Aplastic anemia market seen rising to $9.08 billion by 2030

The global aplastic anemia market is projected to grow from $7.01 billion in 2025 to $7.43 billion in 2026, with long-term demand expected to push it to $9.08 billion by 2030. The Business Research Company points to personalized medicine, stem cell treatment, and rare disease research as key growth drivers.

Why it matters: - The aplastic anemia market is expanding as rare disease diagnosis and treatment infrastructure improve. - Growth could mean broader access to immunosuppressive therapies, bone marrow transplantation, and supportive care for patients with a serious blood disorder. - The market’s projected rise signals continued investment in rare hematology and regenerative medicine.

What happened: - The Business Research Company released The Outlook for the Aplastic Anemia Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the aplastic anemia market at $7.01 billion in 2025 and $7.43 billion in 2026. - The report projects the market will reach $9.08 billion by 2030. - The report was distributed from London on November 2, 2026. - A free sample is available through the company’s sample request page.

The details: - The report says the market’s 2025-2026 growth reflects greater clinical awareness of rare blood disorders. - The report also cites wider availability of immunosuppressive drug therapies. - Bone marrow transplant centers and hospital-based treatment infrastructure have also supported growth. - Diagnostic improvements have helped expand the market. - The report forecasts a 5.1% CAGR from 2026 to 2030. - The report links future growth to regenerative medicine, personalized hematology, rare disease research, stem cell donor registries, and immunomodulatory drugs. - Aplastic anemia is a rare disorder in which bone marrow fails to make enough red blood cells, white blood cells, and platelets. - Symptoms can include extreme fatigue, recurrent infections, and easier bleeding or bruising. - Treatment ranges from medicines that stimulate blood cell production to bone marrow transplantation in severe cases. - The report says key market trends include targeted immunosuppressive therapies, stem cell and bone marrow transplantation, earlier diagnosis, personalized treatment, and supportive care management. - The report also says the market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The full report is available through the company’s report page.

Between the lines: - Personalized medicine is becoming a bigger commercial force in rare disease care. - The report cites February 2024 FDA approvals of 16 new personalized therapies for rare diseases in 2023, more than double the 2022 total, as evidence of that shift. - North America held the largest regional market share in 2025 because of advanced healthcare infrastructure and extensive clinical research. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report’s expanded 2026 format adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics, and future trend analysis.

What’s next: - Market growth is likely to track adoption of personalized hematology treatments and new immunomodulatory drugs. - Expansion of stem cell donor registries and regenerative medicine research could further support demand. - Faster diagnosis and broader transplant access may shape where and how treatment demand grows. - The Business Research Company expects regional growth to remain strongest in Asia-Pacific while North America retains a large share.

The bottom line: - The aplastic anemia market is moving from niche treatment toward a more mature rare-disease segment, with technology, diagnosis, and personalized care driving the next phase of growth.